360° SearchNetwork Hot Spots Trends Time Series

ThromboGenics NV

Type: Company

Name: ThromboGenics NV

First reported May 16 2013 - Updated May 17 2013 - 2 reports

ThromboGenics Declines After Eye Drug Fails in Mid-Stage Trial

May 17 (Bloomberg) -- ThromboGenics NV fell the most in almost four months after reporting that its eye drug Jetrea, which the company began selling in the U.S. this year, failed in a mid-stage study targeting an expanded use.The shares fell as much as ... [Published Washington Post - May 17 2013]

Entities: ThromboGenics NV, Drugs, Patient, Jan De Kerpel, Kristen Hallam

First reported May 16 2013 - Updated May 16 2013 - 1 reports

ThromboGenics NV (TBGNF) Business Update

Staying up-to-date has never been simpler. Sign up for the today! LEUVEN, Belgium, May 16, 2013 /PRNewswire/ - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic ... [Published BioSpace - May 16 2013]

Entities: ThromboGenics NV, Alcon Inc, Leuven (Belgium), Ophthalmic

First reported May 16 2013 - Updated May 16 2013 - 1 reports

ThromboGenics NV Business Update

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!LEUVEN, Belgium, May 16, 2013 /PRNewswire/ - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing ... [Published BioSpace - May 16 2013]

Entities: ThromboGenics NV, Leuven (Belgium), Ophthalmic

First reported May 16 2013 - Updated May 16 2013 - 2 reports

ThromboGenics Business Update

/PRNewswire/ --JETREA ® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 millionPhase IIa study evaluating JETREA ® in wet AMD patients shows 24% VMA resolution rate for JETREA ® treated patients, ... [Published Benzinga.com - May 16 2013]

Entities: ThromboGenics NV, Alcon Inc, European Medicines Agency, Patient

First reported May 13 2013 - Updated May 13 2013 - 2 reports

Antisense Therapeutics Ltd

Just Published: Global Diabetic Retinopathy Market 2012-2016 - MarketResearchReports.Biz

TechNavio's analysts forecast the Global Diabetic Retinopathy Market to grow at a CAGR of 35.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increase in Diabetic Population Worldwide. The Global Diabetic ... [Published MyNewsDesk - May 13 2013]

Entities: Market, Novagali Pharma SA, Excaliard Pharmaceuticals Inc, Antisense Therapeutics Ltd

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Alcon Inc

ThromboGenics’ JETREA Available in Germany Public and Private Market

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its partner Alcon has launched JETREA in Germany, the second European market where the product is now ... [Published Pharma-Mag - May 05 2013]

Entities: ThromboGenics NV, Alcon Inc, Germany, Patient

First reported May 03 2013 - Updated May 03 2013 - 1 reports

NYSE Euronext Inc

THROMBOGENICS: NV increases share capital through warrant exercises

- ThromboGenics NV (NYSE Euronext: THR), an integrated biopharmaceutical company focused on developing innovative ophthalmic medicines, announced today a capital increase arising from employee warrant exercises.Since its inception in 2006, ThromboGenics ... [Published 4 Traders - May 03 2013]

Entities: ThromboGenics NV, Ophthalmic, NYSE Euronext Inc

First reported May 03 2013 - Updated May 03 2013 - 1 reports

ThromboGenicsâ partner Alcon introduces JETREA in Germany public, private markets

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that its partner Alcon has launched JETREA in Germany, the second European market where the product is now available. ... [Published PharmaBiz - May 03 2013]

Entities: Alcon Inc, ThromboGenics NV, Germany, Patient

First reported May 02 2013 - Updated May 02 2013 - 3 reports

THROMBOGENICS : ThromboGenics' JETREA® available in Germany public and private market

- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in Germany, the second European ... [Published 4 Traders - May 02 2013]

Entities: ThromboGenics NV, Alcon Inc, Germany, Patient

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

ThromboGenics' partner Alcon launches vitreomacular traction drug in UK

ThromboGenics NV, a biopharmaceutical company focused on developing and ophthalmic and oncology medicines, has announced that its partner Alcon has launched JETREA, used for the treatment of vitreomacular traction, in the UK. According to ThromboGenics, ... [Published Individual.com - Apr 19 2013]

Entities: ThromboGenics NV, Alcon Inc, Drugs, United Kingdom, Patrik De Haes

First reported Apr 13 2013 - Updated Apr 13 2013 - 1 reports

Alcon launches JETREA in UK; the first medicine for treating vitreomacular traction

ThromboGenics NV, an integrated biopharma company focused on developing and commercializing innovative ophthalmic and oncology medicines, announced that its partner Alcon has launched JETREA (ocriplasmin) in the UK, its first market in Europe. The first ... [Published PharmaBiz - Apr 13 2013]

Entities: Alcon Inc, ThromboGenics NV, United Kingdom, Patrik De Haes, Protein

First reported Mar 18 2013 - Updated Mar 19 2013 - 1 reports

European Union approves ThromboGenicsâ Jetrea for the treatment of vitreomacular traction

The European Commission has approved ThromboGenics' Jetrea (ocriplasmin) in the European Union. Jetrea is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 mi ... [Published PharmaBiz - Mar 18 2013]

Entities: ThromboGenics NV, Alcon Inc, European Union, Vitrectomy

Quotes

Dr Patrik De Haes, CEO of ThromboGenics, said: "The start of 2013 has been a very positive period for ThromboGenics with our lead product JETREA® being launched in the US and Europe. As a result, patients and physicians on both sides of the Atlantic now have access to the first pharmacological treatment for symptomatic VMA/VMT, an important sight-threatening condition. We are pleased with the positive reaction to JETREA® from the US retina community, and are confident that this momentum will continue."

THROMBOGENICS: Business Update [Published 4 Traders - May 16 2013]

Prof. Albert Augustin, Ophthalmology Department Head at Klinikum Karlsruhe, said: "The introduction of JETREA® into Germany represents a significant advancement in the way retina specialist can treat vitreomacular traction and certain stages of macular holes. These vision-threatening conditions, associated with many common retinal disorders, are more frequently identified due to the advancement of new ophthalmic diagnostics, optical coherence tomography, and had been previously addressed by the limited options of either physician observation or vitrectomy. JETREA® now offers a new and effective treatment option, particularly for those patients whose conditions are not yet advanced enough to warrant surgery, to help physicians restore patient´s vision and improve overall quality of life."

THROMBOGENICS : ThromboGenics' JETREA® available in Germany public and private market [Published 4 Traders - May 02 2013]

...launch by Alcon in $ Germany $ is a key step in making this exciting new pharmacological treatment for VMT available to more patients in $ Europe . " JETREA ® contains the active substance ocriplasmin. It is administered through a one-time, single intravitreal injection to treat adults with vitreomacular traction (VMT)."

ThromboGenics' JETREA® Available in Germany Public and Private Market [Published Barchart - May 02 2013]

Dr Patrik De Haes, CEO of ThromboGenics, says: "The launch of JETREA in Europe by Alcon so shortly after gaining European approval is testimony of our joint commitment to ensuring patients in Europe have access to this innovative drug as soon as possible. The additional E45 million payment from Alcon for reaching this milestone means we are well placed to continue investing in the commercialization of JETREA in the US via our own commercial organization. We expect that Alcon will roll out JETREA into other European markets in the coming months and are working with our partner to ensure that all the support for physicians, payers and patients is fully in place."

ThromboGenics' partner Alcon launches vitreomacular traction drug in UK [Published Individual.com - Apr 19 2013]

More Content

sort by: Date \| Relevance
ThromboGenics Declines After Eye Drug Fails in ... [Published Washington Post - May 17 2013]
ThromboGenics NV (TBGNF) Business Update [Published BioSpace - May 16 2013]
ThromboGenics NV Business Update [Published BioSpace - May 16 2013]
ThromboGenics Reports Jetrea Sales as Drug Fail... [Published Washington Post - May 16 2013]
ThromboGenics Business Update [Published Benzinga.com - May 16 2013]
THROMBOGENICS: Business Update [Published 4 Traders - May 16 2013]
Just Published: Global Diabetic Retinopathy Mar... [Published MyNewsDesk - May 13 2013]
Global Diabetic Retinopathy Market 2012-2016 \| ... [Published MyNewsDesk - May 13 2013]
ThromboGenics’ JETREA Available in Germany Publ... [Published Pharma-Mag - May 05 2013]
THROMBOGENICS: NV increases share capital throu... [Published 4 Traders - May 03 2013]
ThromboGenicsâ partner Alcon introduces JETREA ... [Published PharmaBiz - May 03 2013]
THROMBOGENICS : ThromboGenics' JETREA® availabl... [Published 4 Traders - May 02 2013]
ThromboGenics' JETREA(R) Available in Germany P... [Published Zecco - May 02 2013]
ThromboGenics' JETREA® Available in Germany Pub... [Published Barchart - May 02 2013]
ThromboGenics' JETREA® Available in Germany Pub... [Published PR Newswire: Health - May 02 2013]
ThromboGenics' partner Alcon launches vitreomac... [Published Individual.com - Apr 19 2013]
:: Allegro moves ahead on two studies [Published Retinal Physician - Apr 17 2013]
Alcon launches JETREA in UK; the first medicine... [Published PharmaBiz - Apr 13 2013]
ThromboGenics' JETREA®, the First and Only Medi... [Published PR Newswire: General Business - Apr 11 2013]
European Union approves ThromboGenicsâ Jetrea f... [Published PharmaBiz - Mar 18 2013]
ThromboGenics Starts Trading as Part of the BEL... [Published Financial Services - Mar 18 2013]
ThromboGenics' JETREA® Granted EU Approval for ... [Published PR Newswire: Policy & Public Interest - Mar 15 2013]
ThromboGenics Announces Business Update and 201... [Published PR Newswire: Health - Mar 14 2013]
Study shows anti-PlGF agent, TB-403 improves pa... [Published PharmaBiz - Mar 02 2013]
New Paper in Cell Highlights the Potential Role... [Published PR Newswire: General Business - Feb 28 2013]
BioInvent: New Paper in Cell Highlights the Pot... [Published Yahoo! Finance - Feb 28 2013]
BioInvent: New Paper in Cell Highlights the Pot... [Published Business Wire Health News - Feb 28 2013]
Ny artikel i Cell visar en potentiell roll för ... [Published GlobeNewswire: Advertising News - Feb 28 2013]
ThromboGenics, Novartis Win EU OK for Jetrea Ey... [Published Bloomberg via Google News - Jan 18 2013]
ThromboGenics to launch Jetrea in US market on ... [Published PharmaBiz - Jan 07 2013]

Blogs

sort by: Date \| Relevance
ThromboGenics’ JETREA Available in Germany Publ... [Published Pharma-Mag - May 05 2013] ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its partner Alcon has launched JETREA in Germany, the second European market where the product is now ...

Press Releases

sort by: Date \| Relevance
ThromboGenics' JETREA® Available in Germany Pub... [Published PR Newswire: Health - May 02 2013]
ThromboGenics' JETREA®, the First and Only Medi... [Published PR Newswire: General Business - Apr 11 2013]
ThromboGenics Starts Trading as Part of the BEL... [Published Financial Services - Mar 18 2013]
ThromboGenics' JETREA® Granted EU Approval for ... [Published PR Newswire: Policy & Public Interest - Mar 15 2013]
ThromboGenics Announces Business Update and 201... [Published PR Newswire: Health - Mar 14 2013]